J&J's Erleada prevails over Astellas, Pfizer’s Xtandi in real-world prostate cancer study

While they were both approved several years back to treat the same two types of prostate cancer, Astellas and Pfizer’s Xtandi has held a larger slice of the market than Johnson & Johnson’s rival medicine Erleada.